Mayo Clinic study finds chemotherapy before surgery improves survival in early-stage pancreatic cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 11:16 ET (22-Jun-2026 15:16 GMT/UTC)
Cold Spring Harbor Laboratory postdoc Jeremy Nigri and colleagues in the Tuveson lab have discovered that the nervous system plays an active role in pancreatic cancer development—even before tumor formation. Disrupting interactions between nerves and fibroblasts could lead to new treatments or make standard procedures like chemo and immunotherapy more effective.
A new study led by researchers at Moffitt Cancer Center found that blood-based DNA markers known as protein epiScores can help predict which colorectal cancer patients face a higher risk of cancer recurrence or death. Results of the study were published in Clinical Epigenetics.
Researchers identified four protein epiScores that were strongly associated with worse outcomes, with patients showing higher levels experiencing a 60% to 70% greater risk of recurrence. One marker, LGALS3BP, was also linked to overall survival, with higher scores associated with an 80% increased risk of death during follow-up.
According to new research in JNCCN, information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival (PFS) and guide treatment planning in patients with rising prostate-specific antigen (PSA) levels following removal of the prostate.
https://doi.org/10.1016/j.apsb.2025.10.031
This new article publication from Acta Pharmaceutica Sinica B, discusses DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer.
https://doi.org/10.1016/j.apsb.2025.10.005
This new article publication from Acta Pharmaceutica Sinica B, discusses the deep learning-based discovery of tetrahydrocarbazoles as broad-spectrum antitumor agents and click-activated strategy for targeted cancer therapy.